A closer look at “Novartis MS Drug Cuts Relapse Rates by One-Third in Pivotal Trials”, exactly as the source publishes it. Novartis has reported that its experimental multiple sclerosis treatment reduced relapse rates by 33% compared to a standard therapy in pivotal clinical trials. The results mark a significant step forward for the Swiss drugmaker as it seeks to expand its neurology portfolio and compete in the growing MS market. While the company did not disclose the specific drug or comparator in the initial announcement, the data suggest a meaningful improvement over existing options.
Multiple sclerosis, a chronic autoimmune disease affecting the central nervous system, impacts over 2.8 million people worldwide, and relapses are a key measure of disease activity. A one-third reduction could translate into fewer hospitalizations and better quality of life for patients. This listing links straight to the original page, where the content is available in full.